ArticleBMC cancer2022
Changing trends in the disease burden of non-melanoma skin cancer globally from 1990 to 2019 and its predicted level in 25 years.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 169 citations in OpenAlex.
- The Role of Nicotinamide as Chemo-Preventive Agent in NMSCs: A Systematic Review and Meta-Analysis.Nutrients · 2023Pooled it
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Trial
- Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Malassezia May Contribute to Basal Cell Carcinoma Development via Inflammatory and Oxidative Stress Pathways.MicrobiologyOpen · 2026Article
- A Prospective Study of Definitive ChemoRadiation With ImmunOtherapy (CRIO) in Locally or Regionally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma.Advances in radiation oncology · 2026Article
- Article
- Basal Cell Carcinoma Research Landscape Overview via Latent Dirichlet Allocation and HJ-Biplot Analysis.Cancers · 2026Review
- Factors associated with incomplete surgical excision of non-melanoma skin cancers: a single-center retrospective cross-sectional study.Annals of medicine and surgery (2012) · 2026Article
- Characterising the urinary excretion of thymidine dimer photolesions in mice.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026Article
- Potential Efficacy of Luteolin in Cutaneous Squamous Cell Carcinoma: A Combined In Vitro and In Vivo Study.Biomolecules · 2026Article
- Comparison of Noninvasive Methods for Diagnosing Basal Cell Carcinoma: A Network Meta-Analysis.Indian dermatology online journal · 2026Article
- Demographic and regional trends in Nonmelanoma skin cancer mortality in the United States, 1999-2020.BMC cancer · 2026Observational
- A brain-inspired computational framework for image-based risk assessment.Scientific reports · 2026Article
- Global regional and national burden of nonmelanoma skin cancer from 1990 to 2021 based on the global burden of disease 2021 study.Discover oncology · 2026Article
- Global, regional and national burden of skin and subcutaneous diseases: a systematic analysis of the Global Burden of Disease Study 2021.International health · 2026Article
- Skin phototypes, UV exposure, and socioeconomic vulnerability in a region of the Brazilian Amazon.International journal of biometeorology · 2026Article
- Increased risk of squamous cell carcinoma based on solar ultraviolet radiation measurements from outdoor workers in Lisbon, Portugal.Frontiers in public health · 2026Observational
- Skin Cancer Among Patients at a Major University Hospital in Saudi Arabia: A Retrospective, Single-Center Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Assessment of behaviors, attitudes, and awareness regarding skin cancer among polish medical and non-medical students: comparative analysis.Frontiers in oncology · 2026Article
- Incidence and mortality of nonmelanoma skin cancer in Europe: current trends and challenges.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe disease burden of non-melanoma skin cancer (NMSC) has become a significant public health threat. We aimed to conduct a comprehensive analysis to mitigate the health hazards of NMSC.
methodsThis study had three objectives. First, we reported the NMSC-related disease burden globally and for different subgroups (sex, socio-demographic index (SDI), etiology, and countries) in 2019. Second, we examined the temporal trend of the disease burden from 1990 to 2019. Finally, we used the Bayesian age-period-cohort (BAPC) model integrated nested Laplacian approximation to predict the disease burden in the coming 25 years. The Norpred age-period-cohort (APC) model and the Autoregressive Integrated Moving Average (ARIMA) model were used for sensitivity analysis.
resultsThe disease burden was significantly higher in males than in females in 2019. The results showed significant differences in disease burden in different SDI regions. The better the socio-economic development, the heavier the disease burden of NMSC. The number of new cases and the ASIR of basal cell carcinoma (BCC) were higher than that of squamous cell carcinoma (SCC) in 2019 globally. However, the number of DALYs and the age-standardized DALYs rate were the opposite. There were statistically significant differences among different countries. The age-standardized incidence rate (ASIR) of NMSC increased from 54.08/100,000 (95% uncertainty interval (UI): 46.97, 62.08) in 1990 to 79.10/100,000 (95% UI: 72.29, 86.63) in 2019, with an estimated annual percentage change (EAPC) of 1.78. Other indicators (the number of new cases, the number of deaths, the number of disability-adjusted life years (DALYs), the age-standardized mortality rate (ASMR), and the age-standardized DALYs rate) showed the same trend. Our predictions suggested that the number of new cases, deaths, and DALYs attributable to NMSC would increase by at least 1.5 times from 2020 to 2044.
conclusionsThe disease burden attributable to NMSC will continue to increase or remain stable at high levels. Therefore, relevant policies should be developed to manage NMSC, and measures should be taken to target risk factors and high-risk groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.